OmniAb (OABI) Cash from Financing Activities (2021 - 2025)
OmniAb's (OABI) quarterly Cash from Financing Activities came in at -$50000.0 in Q4 2025, down 101.3% year-on-year from $3.8 million in Q4 2024, and down 100.18% on a QoQ basis from $27.7 million in Q3 2025.
OmniAb (OABI) Cash from Financing Activities (2021 - 2025) Analysis & Trends
OmniAb (OABI) has 5 years of Cash from Financing Activities data on file, last reported at -$50000.0 in Q4 2025.
- On a quarterly basis, Cash from Financing Activities fell 101.3% year-over-year to -$50000.0 in Q4 2025; TTM through Mar 2026 was $27.9 million, a 110.07% increase from a year earlier, with the FY2025 full-year figure at $27.9 million, up 114.39% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$50000.0, down from $27.7 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for OABI reached as high as $237.0 million in Q3 2021 and fell as low as -$227.4 million in Q4 2021.
- Historically, Cash from Financing Activities has averaged $8.9 million across 5 years, with a median of $357000.0 in 2023.
- Across the five-year window, Cash from Financing Activities soared 4912.28% in 2024 and plunged 101.3% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$227.4 million in 2021, then surged by 144.5% to $101.2 million in 2022, then sank by 100.49% to -$496000.0 in 2023, then jumped by 876.01% to $3.8 million in 2024, then sank by 101.3% to -$50000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$50000.0 in Q4 2025, $27.7 million in Q3 2025, and $236000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50,000.00 |
| Dec 31, 2025 | -50,000.00 |
| Sep 30, 2025 | 27.68 Mn |
| Sep 30, 2025 | 27.68 Mn |
| Jun 30, 2025 | 236,000.00 |
| Jun 30, 2025 | 236,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 3.85 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Sep 30, 2024 | 8.57 Mn |
| Sep 30, 2024 | 8.57 Mn |
| Jun 30, 2024 | 803,000.00 |
| Jun 30, 2024 | 803,000.00 |
| Mar 31, 2024 | -203,000.00 |
| Mar 31, 2024 | -203,000.00 |
| Dec 31, 2023 | -496,000.00 |
| Dec 31, 2023 | -496,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Sep 30, 2023 | 171,000.00 |